

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.- C-273, Sector-63 Noida, Gautam Buddha Nagar,
Uttar Pradesh-201301, Website- www.raymedlab.com

E-mail- raymedlabsltd@gmail.com, Phone no. - 0120-2426900, 9412700300

Date: 24.05.2024

The Head- Listing Compliance
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai-400001

Scrip Code: 531207

Sub: Outcome of Board Meeting pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir(s),

We would like to inform that the Board of Directors in their meeting held today, **i.e. Friday, 24th day of May, 2024** (commenced at **12:30 P.M.** and concluded at **04:20 P.M.**), has inter alia approved and passed the following resolutions:

1. The **Audited Standalone Financial Results** as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter and year ended March 31, 2024. (Copy Enclosed)
2. The Audit Report on Financial Results for the year ended 31st March, 2024 as placed by the Statutory Auditor of the Company. **(Copy Enclosed)**
3. Pursuant to second proviso to Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 a copy of Declaration of unmodified opinion on Auditor's Report on annual financial results for year ended 31st March, 2024. **(Copy Enclosed)**
4. Submission of details of Outstanding Qualified Borrowings and Incremental Qualified Borrowings with reference to SEBI Circular No. SEBI/HO/DDHS/DDHSRACPOD1/P/CIR/2023/172) dated October 19, 2023. We hereby confirm that RAYMED LABS LIMITED is not a Large Corporate (LC) as per the applicability criteria given in aforesaid circular. **(Copy Enclosed)**

Kindly take the above information on your records.

Thanking you,
For Raymed Labs Limited

Ajai Goyal
Whole Time Director
DIN: 02636418

Place: Noida

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.- C-273, Sector-63 Noida, Gautam Buddha Nagar,

Uttar Pradesh-201301, Website- www.raymedlab.com

E-mail- raymedlabsltd@gmail.com, Phone no. - 0120-2426900, 9412700300

Date: 24.05.2024

The Head- Listing Compliance

BSE Limited

Phiroze Jeejeebhoy Towers

Dalal Street, Mumbai-400001

Scrip Code: 531207

Sub: Declaration on Audit Report for the year ended 31st March, 2024

Dear Sir/Madam,

We hereby declare, on behalf of **Raymed Labs Limited** that Audit report in respect to Annual Audited Standalone Financial Results for the period ended 31st March, 2024 submitted by **M/s. A Kay Mehra & Co., Chartered Accountants**, Statutory Auditor of the Company is with **unmodified opinion** of the Statutory Auditor.

Thanking you,

For Raymed Labs Limited

Ajai Goyal

Whole Time Director

DIN: 02636418

Place: Noida

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.- C-273, Sector-63 Noida, Gautam Buddha Nagar,

Uttar Pradesh-201301, Website- www.raymedlab.com

E-mail- raymedlabsltd@gmail.com, Phone no. - 0120-2426900, 9412700300

Date: 24.05.2024

The Head- Listing Compliance

BSE Limited

Phiroze Jeejeebhoy Towers

Dalal Street Mumbai-400001

Scrip Code: 531207

Subject: Submission of details of Outstanding Qualified Borrowings and Incremental Qualified Borrowings with reference to SEBI Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIRJ2023/172 dated October 19, 2023

Dear Sir/ Madam,

With reference to captioned subject, as required we are providing the following details of Outstanding Qualified Borrowings and Incremental Qualified Borrowings along with the Annual Financial Results being filed with Stock Exchange for the Financial Year ending 31st March, 2024.

Sr. No.	Particulars	Amount (Rs. in Crores)
1	Outstanding Qualified Borrowings at the start of the financial year (Rs. In Crores)	2.37
2	Outstanding Qualified Borrowings at the end of the financial year (Rs. In Crores)	2.43
3	Highest credit rating of the company relating to the unsupported bank borrowings or plain vanilla bonds, which have no structuring/support built in.	NA
4	Incremental borrowing done during the year (qualified borrowing) (Rs. In Crores)	0.06
5	Borrowings by way of issuance of debt securities during the year (Rs. In Crores)	NIL

You are requested to take above information on your records.

Thanking you,

For Raymed Labs Limited

Ajai Goyal

Whole Time Director

DIN: 02636418

Place: Noida



INDEPENDENT AUDITORS' REPORT ON STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31ST MARCH, 2024 OF THE COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

To,
THE BOARD OF DIRECTORS OF
RAYMED LABS LIMITED, 103 EMPEROR 1,
SUPERTECH EMERALD COURT, SECTOR 93A,
NOIDA, UTTAR PRADESH – 201304

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying statement of quarterly and year to date standalone financial results of **RAYMED LABS LIMITED** ("the Company") for the quarter ended March 31, 2024 and for the year ended March 31, 2024 ("Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Regulation").

In our opinion and to the best of our information and according to the explanations given to us, these Standalone Financial Results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard;

and

- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India, of the net loss and other comprehensive income and other financial information of the Company for the quarter ended March 31, 2024 and for the year ended March 31, 2024.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We

Deepak Singh

believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results

These quarterly financial results as well as the year-to-date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by Board of Director in term of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter (if any)

We draw attention to:

- (1) During the year Company's administrative & other general expenses are paid by Ajai Goyal (Director) on behalf of the company.
- (2) Material Uncertainty Related to Going Concern: -

The financial statements which indicate that the Company has accumulated losses and its net worth has been substantially eroded, Company has incurred a loss during the current and previous year(s) and, the Company's current liabilities exceeded its current assets as at the balance sheet date and the Company is not doing any business operations from past more than three years. These conditions, indicate the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern.



Our opinion is not modified in respect of this matter.

The Statement includes the results for the Quarter ended March 31, 2024 being the balancing figure between audited figures in respect of the full financial year ended March 31, 2024 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

Our report is not modified in respect of these matters.

For A. Kay. Mehra & Co.
Chartered Accountants
FRN: (050004C)

Deepak Suneja



CA Deepak Suneja
Partner

Membership No- 501957

Date: 24-May-2024

UDIN- 24501957BKBFMN4402

Statement of Standalone Audited Financial Results for the Quarter and Year ended March 31, 2024

Particulars	Amt. (In Lakhs)				
	Quarter Ended			Year Ended	
	31st March, 2024	31st Dec, 2023	31st March, 2023	31st March, 2024	31st March, 2023
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I. Revenue from Operations	0.00	0.00	0.00	0.00	0.00
II. Other Income	0.00	0.00	2.06	0.00	2.06
III. Total Income (I +II)	0.00	0.00	2.06	0.00	2.06
IV. Expenses					
Cost of Material Consumed	0.00	0.00	0.00	0.00	0.00
Purchases of Stock-in-trade	0.00	0.00	0.00	0.00	0.00
Changes in inventories of finished goods, Work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00
Employee Benefits Expenses	0.90	0.90	0.90	3.60	3.75
Finance Costs	0.00	0.00	0.00	0.00	0.00
Depreciation and amortisation expenses	0.21	0.09	0.19	0.48	0.56
Other Expenses	4.11	0.96	8.86	6.08	14.84
Total Expenses (IV)	5.22	1.95	9.95	10.16	19.15
V. Profit/(Loss) before exceptional items and tax (III- IV)	-5.22	-1.95	-7.89	-10.16	-17.09
VI. Exceptional items	0.00	0.00	0.00	0.00	0.00
VII. Profit/(Loss) before tax (V-VI)	-5.22	-1.95	-7.89	-10.16	-17.09
VIII. Tax Expense					
(1) Current tax	0.00	0.00	0.00	0.00	0.00
(2) Deferred tax	0.00	0.00	0.00	0.00	0.00
(3) Previous Year Tax	0.00	0.00	0.00	0.00	0.00
IX. Profit/(Loss) for the period from continuing operations (VII-VIII)	-5.22	-1.95	-7.89	-10.16	-17.09
X. Profit/(Loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00
XI. Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00
XII. Profit/(Loss) from Discontinued operations (after tax) (X-XI)	0.00	0.00	0.00	0.00	0.00
XIII. Profit/(Loss) for the period (IX+XII)	-5.22	-1.95	-7.89	-10.16	-17.09
XIV. Other Comprehensive Income	0.00	0.00	0.00	0.00	0.00
(A) (i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
(B) (i) Items that will be classified to profit or loss	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
XV. Total Comprehensive Income for the period (XIII+XIV)	-5.22	-1.95	-7.89	-10.16	-17.09
(Comprising Profit (Loss) and Other Comprehensive Income for the Period)					
XVI. Paid up Equity Share Capital (Face Value of Rs. 10 Each)	427.35	427.35	427.35	427.35	427.35
XVII. Other Equity	0.00	0.00	0.00	-668.10	-657.94
XVIII. Earnings per equity share (for continuing operation):					
(1) Basic	-0.1221	-0.0456	-0.1847	-0.2378	-0.4000
(2) Diluted	-0.1221	-0.0456	-0.1847	-0.2378	-0.4000
XIX. Earnings per equity share (for discontinued operation):					
(1) Basic	0.0000	0.0000	0.000	0.000	0.0000
(2) Diluted	0.0000	0.0000	0.000	0.000	0.0000
XX. Earnings per equity share (for discontinued & continuing operations)					
(1) Basic	-0.1221	-0.0456	-0.1847	-0.2378	-0.4000
(2) Diluted	-0.1221	-0.0456	-0.1847	-0.2378	-0.4000

Notes:

- (1) The above standalone financial results have been reviewed by Audit Committee at its meeting held on **24th May 2024** and thereafter approved by the Board of Directors at its Meeting held on **24th May 2024**.
- (2) The Statutory Auditors have carried out their audit for the above results under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Statutory Auditor have expressed their unmodified opinion on these results.
- (3) The above result results are prepared in accordance with Indian Accounting Standards ("Ind AS"), the provisions of the Companies Act, 2013 ("the Act"), as applicable and guidelines issued by the Securities and Exchange Board of India ("SEBI"). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
- (4) The IND AS compliant corresponding figures for the period as reported above have not been subjected to review. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
- (5) The figures for the previous period/year have been regrouped/reclassified, wherever necessary, to conform to the current period/year classification
- (6) As the Company's business activity falls within a single segment, therefore "Segment Reporting" are not applicable.
- (7) The figures of the last quarters are the balancing figures between audited figures in respect of the full financial year up to March 31, 2024 and March 31, 2023 and the unaudited published year-to-date figures up to December 31, 2023 and December 31, 2022, being the date of the end of the third quarter of the respective financial years which were subjected to limited review.
- (8) Previous year/periods figures have been regrouped / reclassified, wherever necessary.
- (9) The above financial results of the company are available on the website of the company at www.raymedlab.com and also at www.bseindia.com

For Raymed Labs Limited

Ajai Goyal
Whole Time Director
DIN : 02636418

Date: 24.05.2024
Place : Noida

Statement of Audited Standalone Assets and Liabilities for the year ended March 31, 2024

Particulars	Amount In Lakhs	
	As at 31st March, 2024	As at 31st March, 2023
	(Audited)	(Audited)
ASSETS		
Non current assets		
(a) Property, Plant and Equipment	14.58	15.05
(b) Capital Work in Progress	0.00	0.00
(c) Investment Property	0.00	0.00
(d) Goodwill	0.00	0.00
(e) Other Intangible Assets	0.00	0.00
(f) Intangible assets under development	0.00	0.00
(g) Biological Assets other than bearer plants	0.00	0.00
(h) Financials Assets-		
(i) Investments	0.00	0.00
(ii) Trade Receivables	0.00	0.00
(iii) Loans	0.00	0.00
(iv) Other(to be specified)	0.00	0.00
(i) Deferred tax assets (net)	0.00	0.00
(j) Other non-current assets	0.00	0.00
TOTAL NON-CURRENT ASSETS	14.58	15.05
Current Assets		
(a) Inventories	0.00	0.00
(b) Financials Assets		
(i) Investments	0.00	0.00
(ii) Trade receivables	0.00	0.00
(iii) Cash and cash equivalents	0.05	0.05
(iv) Bank Balance other than (iii) above	0.00	0.00
(v) Loans	0.00	0.00
(vi) Others (to be specified)	0.00	0.00
(c) Current tex Assets	0.00	0.00
(d) Other current Assets	0.45	0.45
TOTAL CURRENT ASSETS	0.50	0.50
TOTAL ASSETS	15.08	15.55
EQUITY AND LIABILITES		
Equity-		
(a) Equity Share Capital	427.35	427.35
(b) Other Equity	-668.10	-657.94
Liabilities		
Non -Current liabilities		
(a) Financials Liabilities		
(i) Borrowings	0.00	0.00
(ii) Trade Payable	0.00	0.00
(iii) Other Financial liabilities (other than specified in item (b) to be specified	243.17	237.10
(b) Provisions	0.00	0.00
(c) Deffered Tax Liabilites (net)	0.00	0.00
(d) Other Non-Current Liabilities	0.00	0.00
TOTAL NON-CURRENT LIABILITIES	243.17	237.10
Current Liabilities		
(a) Financials Liabilities		
(i) Borrowings	0.00	0.00
(ii) Trade Payables	3.83	3.84
(iii) Other Financial liabilities (other than specified in item (c) to be specified	5.00	5.00
(b) Other current liabilities	0.00	0.20
(c) provisions	3.83	0.00
(d) Current Tax Liabiltries	0.00	0.00
TOTAL CURRENT LIABILITIES	12.66	9.04
TOTAL EQUITY AND LIABILITES	15.08	15.55

For Raymed Labs Limited

Ajai Goyal
Whole Time Director
DIN : 02636418

Date: 24.05.2024
Place : Noida

RAYMED LABS LIMITED
CIN: L24111UP1992PLC014240
Reg. off.- C-273, Sector-63 Noida, Gautam Buddha Nagar,
Uttar Pradesh-201301, Website- www.raymedlab.com
E-mail- raymedlabsltd@gmail.com, Phone no. - 0120-2426900, 9412700300

AUDITED STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED 31 MARCH, 2024

	Amount in Lakhs	
	Year ended March 31, 2024 (01.04.2023 to 31.03.2024) (Audited)	Year ended March 31, 2023 (01.04.2022 to 31.03.2023) (Audited)
Particulars		
Cash flow from Operating Activities		
Profit Before Tax	-10.16	-17.09
Adjustments for		
Adjustments for finance costs		
Adjustments for decrease (increase) in inventories		
Adjustments for decrease (increase) in trade receivables, current		
Adjustments for decrease (increase) in trade receivables, non-current		
Adjustments for decrease (increase) in other current assets		
Adjustments for other financial assets, non-current		
Adjustments for other financial assets, current		
Adjustments for other bank balances		
Adjustments for increase (decrease) in trade payables, current	-0.02	0.20
Adjustments for increase (decrease) in trade payables, non-current		
Adjustments for increase (decrease) in other current liabilities	-0.20	0
Adjustments for increase (decrease) in other non-current liabilities		
Adjustments for depreciation and amortisation expense	0.48	0.55
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss		
Adjustments for provisions, current	3.83	-6.48
Adjustments for provisions, non-current		
Adjustments for other financial liabilities, current		
Adjustments for other financial liabilities, non-current	6.07	16.36
Adjustments for unrealised foreign exchange losses/gains		
Adjustments for dividend income		
Adjustments for interest income		
Adjustments for share-based payments		
Adjustments for fair value losses (gains)		
Adjustments for undistributed profits of associates		
Other adjustments for which cash effects are investing or financing cash flow		
Other adjustments to reconcile profit (loss)		
Other adjustments for non-cash items	0.00	6.45
Share of profit and loss from partnership firm or association of persons or limited liability partnerships		
Total adjustments for reconcile profit (loss)	10.16	17.07
Net cash flows from (used in) operations	0.00	-0.02
Dividends received		
Interest paid		
Interest received		
Income taxes paid (refund)		
Other inflows (outflows) of cash		
Net cash flows from (used in) operating activities	0.00	-0.02
Cash flows from used in investing activities		
Cash flows from losing control of subsidiaries or other businesses		
Cash flows used in obtaining control of subsidiaries or other businesses		
Other cash receipts from sales of equity or debt instruments of other entities		
Other cash payments to acquire equity or debt instruments of other entities		
Other cash receipts from sales of interests in joint ventures		
Other cash payments to acquire interests in joint ventures		
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships		
Cash payment for investment in partnership firm or association of persons or limited liability partnerships		
Proceeds from sales of property, plant and equipment		
Purchase of property, plant and equipment		
Proceeds from sales of investment property		
Purchase of investment property		
Proceeds from sales of intangible assets		
Purchase of intangible assets		
Proceeds from sales of intangible assets under development		
Purchase of intangible assets under development		
Proceeds from sales of goodwill		
Purchase of goodwill		
Proceeds from biological assets other than bearer plants		
Purchase of biological assets other than bearer plants		
Proceeds from government grants		
Proceeds from sales of other long-term assets		
Cash receipts from repayment of advances and loans made to other parties		
Cash payments for future contracts, forward contracts, option contracts and swap contracts		
Cash receipts from future contracts, forward contracts, option contracts and swap contracts		
Dividends received		
Interest received		
Income taxes paid (refund)		
Other inflows (outflows) of cash		
Net cash flows from (used in) investing activities	0	0
Cash flows from used in financing activities		
Proceeds from changes in ownership interests in subsidiaries		
Payments from changes in ownership interests in subsidiaries		
Proceeds from issuing shares		
Proceeds from issuing other equity instruments		
Payments to acquire or redeem entity's shares		

Payments of other equity instruments		
Proceeds from exercise of stock options		
Proceeds from issuing debentures notes bonds etc		
Proceeds from borrowings		
Repayments of borrowings		
Payments of finance lease liabilities		
Payments of lease liabilities		
Dividends paid		
Interest Paid		
Income taxes paid (refund)		
Other inflows (outflows) of cash		
Net cash flows from (used in) financing activities	0	0
Net increase (decrease) in cash and cash equivalents before effect of exchange ratechanges	0.00	-0.02
Effect of exchange rate changes on cash and cash equivalents	0	0
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase (decrease) in cash and cash equivalents		-0.02
Cash and cash equivalents cash flow statement at beginning of period	0.05	0.07
Cash and cash equivalents cash flow statement at end of period	0.05	0.05
Notes:		1. The
Cashflow Statement has been prepared under 'Indirect Method' as set out in Ind AS 7 "Statement of CashFlows".		2. Amount in
brackets, represent Cash Outflow.		3.Previous year's year
figures have been regrouped and rearranged wherever necessary.		
For Raymed Labs Limited		
Ajai Goyal		
Whole Time Director		
DIN: 02636418		
Date: 24.05.2024		
Place: Noida		